Objective
While prevention of most female specific cancers (ovarian, breast, endometrial) has not progressed substantially in recent years, significant progress has been made with cervical cancer due to accessibility of the cell of origin (cervical smear) and availability of a test for the causal agent (human papilloma virus); together these enable identification of high risk individuals and interventions to prevent infection or halt progression to invasive cancer.
Our consortium has developed an exciting opportunity to utilise clinically abundant cervical cells in tandem with a multi-omics enabled (genome, epigenome, metagenome) analysis pipeline to understand an individual’s risk of developing a female specific cancer and to direct a personalised screening and prevention strategy. Cervical cells – currently collected within cervical cancer screening – provide an ideal window into other female specific cancers because they are (i) an excellent non-invasive source of high quality DNA, (ii) provide a readout for environmental exposure, (iii) are part of the Müllerian tract and (iv) are hormone sensitive, recording (via the epigenome) various hormonal conditions over a lifetime that trigger cancer development. The FORECEE project is aligned with the novel concept of “P4 Medicine” (predictive, preventive, personalized, and participatory): it aims to translate the risk prediction tool’s output into personalised recommendations for screening and prevention of female cancers.
Our consortium comprises a multi-disciplinary team of experts in clinical oncology, risk-benefit communication, omics technologies, decision analysis, health economics and public health. We will examine the effectiveness of the proposed cervical cell omics analysis method and investigate the legal, social, ethical and behavioural issues related to implementation of the risk prediction tool, through direct interaction with stakeholder groups, to ensure its rapid translation into clinical practice across Europe.
Fields of science
- medical and health scienceshealth sciencespublic health
- medical and health sciencesbasic medicinephysiologycytology
- medical and health sciencesclinical medicineoncologycervical cancer
- social scienceseconomics and businesseconomicshealth economics
- medical and health scienceshealth sciencesinfectious diseasesDNA viruses
Programme(s)
Funding Scheme
RIA - Research and Innovation actionCoordinator
WC1E 6BT London
United Kingdom
See on map
Participants (14)
17177 Stockholm
See on map
116 36 Praha 1
See on map
5021 Bergen
See on map
20121 Milano
See on map
SO16 6YD Southampton
See on map
Legal entity other than a subcontractor which is affiliated or legally linked to a participant. The entity carries out work under the conditions laid down in the Grant Agreement, supplies goods or provides services for the action, but did not sign the Grant Agreement. A third party abides by the rules applicable to its related participant under the Grant Agreement with regard to eligibility of costs and control of expenditure.
SO17 1BJ Southampton
See on map
80539 MUNCHEN
See on map
WC1E 7HT London
See on map
Participation ended
CB2 1TN Cambridge
See on map
3015 GD Rotterdam
See on map
6020 INNSBRUCK
See on map
80539 Munchen
See on map
Participation ended
LN1 1XW Lincoln
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
78467 Konstanz
See on map